Similar articles

• Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

  Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Rostaing L. Kamar N, et al. Am J Transplant. 2010 Jan;10(1):89-98. doi: 10.1111/j.1600-6143.2009.02785.x. Epub 2009 Jul 28. Am J Transplant. 2010. PMID: 19656128
• Is rituximab safe to use in kidney transplant patients?

  Jordan SC, Glotz D. Jordan SC, et al. Am J Transplant. 2010 Jan;10(1):8-9. doi: 10.1111/j.1600-6143.2009.02925.x. Epub 2009 Dec 17. Am J Transplant. 2010. PMID: 19958329 No abstract available.
• Transplantation: rituximab induction for prevention of HLA-antibody rebound.

  Sood P, Hariharan S. Sood P, et al. Nat Rev Nephrol. 2014 Dec;10(12):682-3. doi: 10.1038/nrneph.2014.179. Epub 2014 Oct 7. Nat Rev Nephrol. 2014. PMID: 25287429
• Desensitization across the HLA barrier in kidney transplantaion.

  Mohamed MA, Lorentzen D, Kim J, Djamali A. Mohamed MA, et al. Front Biosci (Schol Ed). 2011 Jun 1;3(3):929-36. doi: 10.2741/197. Front Biosci (Schol Ed). 2011. PMID: 21622242 Review.
• Anti-CD20 Blocker Rituximab in Kidney Transplantation.

  Sood P, Hariharan S. Sood P, et al. Transplantation. 2018 Jan;102(1):44-58. doi: 10.1097/TP.0000000000001849. Transplantation. 2018. PMID: 28614191 Review.